作者
Oscar F Chacón-Camacho, Glustein Pozo-Molina, Claudia Fabiola Méndez-Catalá, Julia Reyes-Reali, René Médndez-Cruz, Juan Carlos Zenteno
发表日期
2022/2/1
期刊
Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders)
卷号
22
期号
2
页码范围
198-211
出版商
Bentham Science Publishers
简介
Knowledge of epidemiology, genetic etiopathogenesis, diagnostic criteria, and management of familial hypercholesterolemia have increased in the last two decades. Several population studies have shown that familial hypercholesterolemia is more frequent than previously thought, making this entity the most common metabolic disease with monogenic inheritance in the world. Identification of causal heterozygous pathogenic variants in LDLR, APOB, and PCSK9 genes has increased diagnostic accuracy of classical criteria (extreme hypercholesterolemia, personal / family history of premature coronary artery disease or other cardiovascular diseases). Genetic screening has been recently introduced in many European countries to detect patients with familial hypercholesterolemia, mainly affected pediatric subjects, asymptomatic or those at the beggining of their disease, to increase surveillance and avoid …
引用总数
学术搜索中的文章
OF Chacón-Camacho, G Pozo-Molina… - Endocrine, Metabolic & Immune Disorders-Drug …, 2022